JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Slēgts

4.05 -1.94

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.01

Max

4.13

Galvenie mērījumi
By Trading Economics
Ienākumi	466K -27M
Pārdošana	2M 15M
Peļņas marža	-178.834
Darbinieki	141
EBITDA	-2M -29M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+254.35% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	24M 252M
Iepriekšējā atvēršanas cena	5.99
Iepriekšējā slēgšanas cena	4.05

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. apr. 00:00 UTC

Peļņas

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026. g. 24. apr. 00:00 UTC

Peļņas

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026. g. 23. apr. 23:47 UTC

Tirgus saruna

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

2026. g. 23. apr. 23:13 UTC

Iegādes, apvienošanās, pārņemšana

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

2026. g. 23. apr. 22:33 UTC

Peļņas

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

2026. g. 23. apr. 22:17 UTC

Peļņas

PLS Executed Offtake Agreement With Ronbay

2026. g. 23. apr. 22:17 UTC

Peļņas

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

2026. g. 23. apr. 22:16 UTC

Peļņas

PLS Commences Commissioning of Midstream Demonstration Plant

2026. g. 23. apr. 22:15 UTC

Peļņas

PLS Group Reaffirms FY26 Guidance for All Metrics

2026. g. 23. apr. 22:14 UTC

Peļņas

PLS Group 3Q Cash Margin From Operations A$461M at March 31

2026. g. 23. apr. 22:14 UTC

Peļņas

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

2026. g. 23. apr. 22:13 UTC

Peļņas

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

2026. g. 23. apr. 22:12 UTC

Peļņas

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

2026. g. 23. apr. 22:12 UTC

Peļņas

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

2026. g. 23. apr. 22:11 UTC

Peļņas

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

2026. g. 23. apr. 22:10 UTC

Peļņas

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

2026. g. 23. apr. 22:09 UTC

Peļņas

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

2026. g. 23. apr. 22:08 UTC

Peļņas

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

2026. g. 23. apr. 22:04 UTC

Peļņas

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

2026. g. 23. apr. 21:56 UTC

Tirgus saruna

Peļņas

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

2026. g. 23. apr. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026. g. 23. apr. 21:27 UTC

Peļņas

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

2026. g. 23. apr. 21:25 UTC

Peļņas

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

2026. g. 23. apr. 21:24 UTC

Peļņas

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

2026. g. 23. apr. 21:24 UTC

Peļņas

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

2026. g. 23. apr. 21:21 UTC

Peļņas

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

2026. g. 23. apr. 21:21 UTC

Peļņas

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

254.35% augšup

Prognoze 12 mēnešiem

Vidējais 14.67 USD 254.35%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.